探索针作为阿尔茨海默病的补充治疗的潜力:推动前进的边界
Rhuann Pontes Dos Santos Silva1, Breno José Alencar Pires Barbosa2,3
1Department of Medicine, Catholic University of Pernambuco, Recife, Brazil.
Journal of Alzheimer's disease : JAD
|February 10, 2025
概括
针作为阿尔茨海默病的补充疗法具有前景,有可能改善认知能力并提供神经保护. 由于研究有限和样本规模小,需要进一步研究.
科学领域:
- 神经科学是一个神经科学.
- 综合医学是一个整体医学.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是认知能力下降.
- 目前的治疗方法具有有限的疗效,这凸显了对新型治疗策略的需求.
- 针正在被探索作为一种辅助疗法,用于AD的症状管理.
研究的目的:
- 评估针作为阿尔茨海默病的辅助疗法的潜在好处.
- 评估针对阿尔茨海默病患者认知功能,神经保护和肠道调节的影响.
- 综合了来自分析和随机临床试验的当前证据,对阿尔茨海默病的针.
主要方法:
- 随机临床试验 (RCT) 的系统审查和元分析.
- 对研究针对阿尔茨海默氏症患者认知评估的影响的研究分析.
- 对针对AD神经保护路径和肠道微生物群的影响研究的审查.
主要成果:
- 针在改善阿尔茨海默病患者的认知功能方面显示出潜在的好处.
- 有证据表明,针可以积极调节与神经保护相关的信号通路.
- 研究表明,在阿尔茨海默病的背景下,针在调节肠道微生物群方面可能发挥作用.
结论:
- 针为阿尔茨海默氏病提供了一个有前途的辅助症状治疗方法.
- 需要使用更大的样本大小进行进一步的高质量研究,以证实疗效和阐明机制.
- 在AD中,针治疗的核心治疗目标的详细映射对于临床优化是必要的.
相关概念视频
Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155
Alzheimer's Disease: Overview
432
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
432


